6CYM

Reversible Covalent Direct Thrombin Inhibitors

Summary for 6CYM

• Entry DOI: 10.2210/pdb6cym/pdb
• Descriptor: Prothrombin, 2-methoxybenzoic acid, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (6 entities in total)
• Functional Keywords: hydrolase, blood coagulation, plasma, calcium-binding, glycoprotein, serine protease, hydrolase-hydrolase inhibitor complex, hydrolase/hydrolase inhibitor
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 4
• Total formula weight: 66739.35

Authors

Sivaraja, M.,Williams, D.C. (deposition date: 2018-04-06, release date: 2018-05-09, Last modification date: 2024-11-13)

Primary citation

Sivaraja, M.,Pozzi, N.,Rienzo, M.,Lin, K.,Shiau, T.P.,Clemens, D.M.,Igoudin, L.,Zalicki, P.,Chang, S.S.,Estiarte, M.A.,Short, K.M.,Williams, D.C.,Datta, A.,Di Cera, E.,Kita, D.B.
Reversible covalent direct thrombin inhibitors.
PLoS ONE, 13:e0201377-e0201377, 2018

PubMed Abstract: In recent years, the traditional treatments for thrombotic diseases, heparin and warfarin, are increasingly being replaced by novel oral anticoagulants offering convenient dosing regimens, more predictable anticoagulant responses, and less frequent monitoring. However, these drugs can be contraindicated for some patients and, in particular, their bleeding liability remains high.

PubMed: 30071045
DOI: 10.1371/journal.pone.0201377

Experimental method

X-RAY DIFFRACTION (2.9 Å)